« Back to Record
Schram, A. A., Colombo, N., Arrowsmith, E., Narayan, V., Yonemori, K., Scambia, G., Zelnak, A. A., Bauer, T. T., Jin, N., Ulahannan, S. S., Colleoni, M. A., Aftimos, P., Donoghue, M. M., Rosen, E., Rudneva, V. V., Telli, M. M., Domchek, S. S., Galsky, M. D., Hoyle, M., Chappey, C., Stewart, R., Blake-Haskins, J. J., & Yap, T. A. (2023). Avelumab Plus Talazoparib in Patients with BRCA1/2 - Or ATM -Altered Advanced Solid Tumors: Results from JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial. JAMA oncology, 9(7), 1009. doi:10.1001/jamaoncol.2022.5218
Citation APA
Permalink
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/374663



